Skip to main content


Page 32 of 38

  1. The aberrant activation of Ras signaling is associated with human diseases including hematological malignancies and vascular disorders. So far the pathological roles of activated Ras signaling in hematopoiesis...

    Authors: Chun-Guang Ren, Lei Wang, Xiao-E Jia, Yi-Jie Liu, Zhi-Wei Dong, Yi Jin, Yi Chen, Min Deng, Yong Zhou, Yi Zhou, Rui-Bao Ren, Wei-Jun Pan and Ting-Xi Liu
    Citation: Journal of Hematology & Oncology 2013 6:34
  2. Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells appears to be a promising immunotherapeutic strategy. CAR combines the specificity of antibody and cytotoxicity of cytotoxic T lymphocytes,...

    Authors: Chan-Juan Shen, Yu-Xiu Yang, Ethan Q Han, Na Cao, Yun-Fei Wang, Yi Wang, Ying-Ying Zhao, Li-Ming Zhao, Jian Cui, Puja Gupta, Albert J Wong and Shuang-Yin Han
    Citation: Journal of Hematology & Oncology 2013 6:33
  3. The Austrian Azacitidine Registry is a multi-center database ( NCT01595295). The nature and intent of the registry was to gain a comprehen...

    Authors: Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller, Martin Schreder, Christoph Tinchon, Michael Pfeilstocker, Susanne Steinkirchner, Thomas Melchardt, Martina Mitrovic, Michael Girschikofsky, Alois Lang, Peter Krippl, Thamer Sliwa, Alexander Egle, Werner Linkesch, Daniela Voskova…
    Citation: Journal of Hematology & Oncology 2013 6:32
  4. Anti-VEGF therapy reduces tumor blood vessels, however, some vessels always remain. These VEGF insensitive vessels may help support continued tumor growth and metastases. Many in vitro assays examining multiple s...

    Authors: Beverly L Falcon, Belinda O’Clair, Don McClure, Glenn F Evans, Julie Stewart, Michelle L Swearingen, Yuefeng Chen, Kevin Allard, Linda N Lee, Kuldeep Neote, Dyke P McEwen, Mark T Uhlik and Sudhakar Chintharlapalli
    Citation: Journal of Hematology & Oncology 2013 6:31
  5. The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation h...

    Authors: Tiangui Huang, Michael Karsy, Jian Zhuge, Minghao Zhong and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:30
  6. Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating...

    Authors: Lieke H van der Helm, Ellen RM Scheepers, Nic JGM Veeger, Simon MGJ Daenen, André B Mulder, Eva van den Berg, Edo Vellenga and Gerwin Huls
    Citation: Journal of Hematology & Oncology 2013 6:29
  7. The definition of immune Thrombocytopenia (ITP) as a peripheral blood platelet count less than 100 × 109/L instead of the historical criteria of 150 × 109/L renders subjects with platelets between 100 and 150 × 1...

    Authors: Andreia Maria Camargos Rocha, Cláudia Souza, Gifone Aguiar Rocha, Fabrício Freire de Melo, Nelma Cristina Diogo Clementino, Marília Campos Abreu Marino and Dulciene Maria Magalhães Queiroz
    Citation: Journal of Hematology & Oncology 2013 6:28
  8. Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametin...

    Authors: Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:27
  9. The predominant mechanism by which human tumors maintain telomere length is via telomerase. In ~10% of tumor samples, however, telomere length is conserved, despite no detectable telomerase activity, in part t...

    Authors: Oumar Samassekou, Abba Malina, Josée Hébert and Ju Yan
    Citation: Journal of Hematology & Oncology 2013 6:26
  10. Transcription factor PU.1, a member of the ETS family, is a master regulator of myeloid differentiation whose functional disruption is often associated with acute myeloid leukemia (AML). Although much has been...

    Authors: Maoxiang Qian, Wen Jin, Xuehua Zhu, Xiaohong Jia, Xianwen Yang, Yanzhi Du, Kankan Wang and Ji Zhang
    Citation: Journal of Hematology & Oncology 2013 6:25
  11. Inosine triphosphate pyrophosphohydrolase (ITPase) is a ‘house-cleaning’ enzyme that degrades non-canonical (‘rogue’) nucleotides. Complete deficiency is fatal in knockout mice, but a mutant polymorphism resul...

    Authors: Mazin A Zamzami, John A Duley, Gareth R Price, Deon J Venter, John W Yarham, Robert W Taylor, Laurence P Catley, Timothy HJ Florin, Anthony M Marinaki and Francis Bowling
    Citation: Journal of Hematology & Oncology 2013 6:24
  12. p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A breakthrough in cancer research came from the discovery of the drugs which are capable of reactivating p53 function. Most an...

    Authors: Manujendra N Saha, Lugui Qiu and Hong Chang
    Citation: Journal of Hematology & Oncology 2013 6:23
  13. Lynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch...

    Authors: Yiying Wang, Yue Wang, Jie Li, Janiel Cragun, Kenneth Hatch, Setsuko K Chambers and Wenxin Zheng
    Citation: Journal of Hematology & Oncology 2013 6:22
  14. Activating mutations [internal tandem duplication (ITD)] or overexpression of the FMS-like tyrosine kinase receptor-3 (FLT3) gene are associated with poor outcome in acute myeloid leukemia (AML) patients, undersc...

    Authors: Houda Alachkar, Ramasamy Santhanam, Jason G Harb, David M Lucas, Joshua J Oaks, Christopher J Hickey, Li Pan, A Douglas Kinghorn, Michael A Caligiuri, Danilo Perrotti, John C Byrd, Ramiro Garzon, Michael R Grever and Guido Marcucci
    Citation: Journal of Hematology & Oncology 2013 6:21
  15. There are multiple sources of reactive oxygen species (ROS) in the cell. As a major site of ROS production, mitochondria have drawn considerable interest because it was recently discovered that mitochondrial R...

    Authors: Xinyuan Li, Pu Fang, Jietang Mai, Eric T Choi, Hong Wang and Xiao-feng Yang
    Citation: Journal of Hematology & Oncology 2013 6:19
  16. Acute myeloid leukemia (AML) is a heterogeneous disorder with aberrant regulation of a variety of signal pathways. Therefore, simultaneous targeting of two or even more deregulated signal transduction pathways...

    Authors: Haitao Meng, Yingming Jin, Hui Liu, Liangshun You, Chunmei Yang, Xue Yang and Wenbin Qian
    Citation: Journal of Hematology & Oncology 2013 6:18
  17. Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet ag...

    Authors: Ted Wun, Denis Soulieres, Andrew L Frelinger, Lakshmanan Krishnamurti, Enrico M Novelli, Abdullah Kutlar, Kenneth I Ataga, Charles L Knupp, Lillian E McMahon, John J Strouse, Chunmei Zhou, Lori E Heath, Chuke E Nwachuku, Joseph A Jakubowski, Jeffrey S Riesmeyer and Kenneth J Winters
    Citation: Journal of Hematology & Oncology 2013 6:17
  18. We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoi...

    Authors: Hui Liu, Xiao Zhai, Zhaoyang Song, Jing Sun, Yang Xiao, Danian Nie, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Sanfang Tu, Yonghua Li, Xutao Guo, Guopan Yu and Qifa Liu
    Citation: Journal of Hematology & Oncology 2013 6:15
  19. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive tha...

    Authors: Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Shuichi Taniguchi, Takashi Okamura, Eiichi Ohtsuka, Takashi Yoshida, Masakazu Higuchi, Goichi Yoshimoto, Tomoaki Fujisaki, Yasunobu Abe, Yasushi Takamatsu, Shouhei Yokota, Koichi Akashi and Mine Harada
    Citation: Journal of Hematology & Oncology 2013 6:14
  20. The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to vali...

    Authors: Desiree Jones, Elisabeth G Vichaya, Xin Shelley Wang, Loretta A Williams, Nina D Shah, Sheeba K Thomas, Valen E Johnson, Richard E Champlin, Charles S Cleeland and Tito R Mendoza
    Citation: Journal of Hematology & Oncology 2013 6:13
  21. The human c-mpl gene (MPL) plays an important role in the development of megakaryocytes and platelets as well as the self-renewal of haematopoietic stem cells. However, numerous MPL mutations have been identified...

    Authors: Xin He, Zhigang Chen, Yangyan Jiang, Xi Qiu and Xiaoying Zhao
    Citation: Journal of Hematology & Oncology 2013 6:11
  22. We investigated the utility of bioluminescence imaging (BLI) using firefly luciferase in monoclonal and polyclonal populations of leukemia cells in vitro and in vivo.

    Authors: Sandra Christoph, Jennifer Schlegel, Francesca Alvarez-Calderon, Yong-Mi Kim, Luis N Brandao, Deborah DeRyckere and Douglas K Graham
    Citation: Journal of Hematology & Oncology 2013 6:10
  23. Interactions between genetic variants and risk factors in myelodysplastic syndromes are poorly understood. In this case–control study, we analyzed 1 421 single nucleotide polymorphisms in 408 genes involved in...

    Authors: Monika Belickova, Michaela Dostalova Merkerova, Eliska Stara, Jitka Vesela, Dana Sponerova, Dana Mikulenkova, Radim Brdicka, Radana Neuwirtova, Anna Jonasova and Jaroslav Cermak
    Citation: Journal of Hematology & Oncology 2013 6:9
  24. Previous studies demonstrated that selenite induced cancer-cell apoptosis through multiple mechanisms; however, effects of selenite on microtubules in leukemic cells have not been demonstrated.

    Authors: Kejian Shi, Qian Jiang, Zhushi Li, Lei Shan, Feng Li, JiaJia An, Yang Yang and Caimin Xu
    Citation: Journal of Hematology & Oncology 2013 6:7
  25. MicroRNAs (miRNAs) are emerging as a novel class of non-coding RNA molecules that regulate gene expression at a post-transcriptional level. More than 1000 miRNAs have been identified in human cells to date, an...

    Authors: Yu-Meng Sun, Kang-Yu Lin and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2013 6:6
  26. Tissue factor (TF) pathway inhibitor-1 (TFPI) is expressed in several malignant tissues- and cell lines and we recently reported that it possesses anti-tumor effects in breast cancer cells, indicating a biolog...

    Authors: Benedicte Stavik, Mari Tinholt, Marit Sletten, Grethe Skretting, Per Morten Sandset and Nina Iversen
    Citation: Journal of Hematology & Oncology 2013 6:5
  27. To assess if intensity-modulated radiotherapy (IMRT) can possibly lead to improved local control and lower incidence of vision impairment/blindness in comparison to non-IMRT techniques when treating sinonasal ...

    Authors: Alexander Chi, Nam P Nguyen, William Tse, Gill Sobremonte, Patrick Concannon and Angela Zhu
    Citation: Journal of Hematology & Oncology 2013 6:4
  28. Notch1 is a potent regulator known to play an oncogenic role in many malignancies including T-cell acute lymphoblastic leukemia (T-ALL). Tumor hypoxia and increased hypoxia-inducible factor-1α (HIF-1α) activit...

    Authors: Jie Zou, Peng Li, Fei Lu, Na Liu, Jianjian Dai, Jingjing Ye, Xun Qu, Xiulian Sun, Daoxin Ma, Jino Park and Chunyan Ji
    Citation: Journal of Hematology & Oncology 2013 6:3
  29. Despite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma (MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo) ...

    Authors: Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, Taiga Nishihori, William Bensinger, Benjamin Djulbegovic and Ambuj Kumar
    Citation: Journal of Hematology & Oncology 2013 6:2
  30. Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white...

    Authors: James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2013 6:1
  31. A previous study has demonstrated a significant decrease in the TCRζ gene expression level in chronic myeloid leukemia (CML); thus, we further investigated the expression of TCRζ-regulating factors, the distri...

    Authors: Xianfeng Zha, Xiaojuan Yan, Qi Shen, Yuping Zhang, Xiuli Wu, Shaohua Chen, Bo Li, Lijian Yang, Suxia Geng, Jianyu Weng, Xin Du and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2012 5:74
  32. Stem cell factor (SCF) activates hematopoietic stem cell (HSC) self-renewal and is being used to stimulate the ex vivo expansion of HSCs. The mechanism by which SCF supports expansion of HSCs remains poorly un...

    Authors: Jie Fan, Xinxin Ding and Yongping Jiang
    Citation: Journal of Hematology & Oncology 2012 5:73
  33. Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and ...

    Authors: Eunice S Wang, Roger M Lyons, Richard A Larson, Sunil Gandhi, Delong Liu, Carmen Matei, Bart Scott, Kuolung Hu and Allen S Yang
    Citation: Journal of Hematology & Oncology 2012 5:71
  34. Promotion of endothelial normalization restores tumor oxygenation and obstructs tumor cells invasion, intravasation, and metastasis. We therefore investigated whether a vasoactive drug, tanshinone IIA, could i...

    Authors: Wen-Quan Wang, Liang Liu, Hui-Chuan Sun, Yan-Ling Fu, Hua-Xiang Xu, Zong-Tao Chai, Qiang-Bo Zhang, Ling-Qun Kong, Xiao-Dong Zhu, Lu Lu, Zheng-Gang Ren and Zhao-You Tang
    Citation: Journal of Hematology & Oncology 2012 5:69
  35. Pancreatic cancer (PC) is a lethal malignancy primarily driven by activated Kras mutations and characterized by the deregulation of several genes including mucins. Previous studies on mucins have identified their...

    Authors: Satyanarayana Rachagani, María P Torres, Sushil Kumar, Dhanya Haridas, Michael Baine, Muzafar A Macha, Sukhwinder Kaur, Moorthy P Ponnusamy, Parama Dey, Parthasarathy Seshacharyulu, Sonny L Johansson, Maneesh Jain, Kay-Uwe Wagner and Surinder K Batra
    Citation: Journal of Hematology & Oncology 2012 5:68
  36. The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituxi...

    Authors: Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie-Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri A Elsayed and Bertrand Coiffier
    Citation: Journal of Hematology & Oncology 2012 5:67
  37. The discovery of miRNAs has revolutionized the way we examine the genome, RNA products, and the regulation of transcription and translation. Their ability to modulate protein expression through mRNA degradatio...

    Authors: Anthony Virtue, Hong Wang and Xiao-feng Yang
    Citation: Journal of Hematology & Oncology 2012 5:66
  38. von Willebrand factor (vWF) is a multimeric glycoprotein essential for hemostasis after vascular injury, which modulates platelet-surface and platelet–platelet interactions by linking platelet receptors to the...

    Authors: Hailong Yuan, Ning Deng, Songmei Zhang, Yange Cao, Qiong Wang, Xin Liu and Qing Zhang
    Citation: Journal of Hematology & Oncology 2012 5:65
  39. Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standar...

    Authors: Shundong Cang, Nikhil Mukhi, Kemeng Wang and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:64
  40. In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receivin...

    Authors: Chongrui Xu, Qing Zhou and Yi-long Wu
    Citation: Journal of Hematology & Oncology 2012 5:62
  41. The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT an...

    Authors: Giovanni Ponti, Aldo Tomasi and Giovanni Pellacani
    Citation: Journal of Hematology & Oncology 2012 5:60

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    9,883 Altmetric mentions 

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here